Product Description
TRPH-222 is a novel CD22-targeting antibody-drug conjugate with a unique efficacy and safety profile that has successfully passed the Phase 1 test. It demonstrated robust clinical activity in NHL, with durable complete responses that were enriched in FL patients. (Sourced from: https://www.oncozine.com/trph-222-a-novel-adc-shows-positive-results-in-the-treatment-of-b-cell-non-hodgkins-lymphoma/#:~:text=%E2%80%9CTRPH%2D222%20is%20a%20novel,were%20enriched%20in%20FL%20patients.)
Mechanisms of Action: CD22 Antagonist
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Triphase Research and Development III
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: B-Cell Marginal Zone Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Lymphoma, Non-Hodgkin|Mantle-Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TRPH-222-100 | P1 |
Completed |
Lymphoma, Non-Hodgkin|B-Cell Marginal Zone Lymphoma|Diffuse Large B-Cell Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma |
2021-11-17 |
30% |